Findings of a meta-analysis show that pioglitazone use with a dose duration greater than 438 days was associated with a significantly reduced risk of Parkinson disease in patients with diabetes.
Pioglitazone use among patients with diabetes was associated with a significantly reduced risk of Parkinson disease (PD), according to study findings published in Journal of Clinical Neuroscience.
PD is the fastest growing neurological condition worldwide, threatening the physical and mental health of middle-aged and elderly people. Prior research has shown that PD diagnosis is associated with significant economic burden, in which nonacute institutional care, inpatient hospitalization, and outpatient care are the largest drivers of cost among differing coverage plans.
Although the specific pathogenesis and etiology of PD are not fully clarified, diabetes has been indicated to potentially share similar pathophysiology with the neurodegenerative condition and to be a risk factor for development.
“Thus, antihyperglycemic agents may have beneficial effects on PD. Pioglitazone is a peroxisome proliferator activated receptor (PPAR) agonist that can improve hyperglycemia and insulin resistance… and the treatment effect of pioglitazone as a neuroprotective agent for PD has been confirmed in nonhuman primate and rodent models,” said the study authors. “However, whether pioglitazone can minimize the risk of PD in patients with diabetes remains controversial.”
Researchers conducted a systematic review and meta-analysis to evaluate the effect of pioglitazone on PD in patients with diabetes, as well as the association between dose-duration-day (DDD) of the drug and risk of PD.
Studies within the PubMed, Embase, and Web of Science databases from inception to July 22, 2021, were examined during the review, with the Newcastle-Ottawa scale (NOS) used to evaluate the quality of the eligible studies. The studies were divided into at least 3 dose groups based on the DDD of pioglitazone.
After eliminating duplicate studies, 540 studies were obtained, of which only 3 retrospective cohort studies met the inclusion criteria and were relevant for the meta-analysis.
The studies were conducted in Taiwan and the United Kingdom with 131,410 participants, and the publication years ranged from 2015 to 2020. Across the overall patient cohort, the mean age and follow-up duration were 57.91 to 63.60 and 5 to 6.13 years, respectively. The NOS score of the eligible studies was 7-8, suggesting that the included studies had relatively high quality.
Results of the meta-analysis showed there was a significant reduction in the risk of PD among pioglitazone users vs nonusers with diabetes (risk ratio [RR], 0.87; 95% CI, 0.62-0.99; P = .039).
After accounting for dose response, no significant difference in PD risk was noted in patients with diabetes taking 438 DDDs of pioglitazone or lower compared with nonusers. When the DDD of pioglitazone was 438, a 15% lower risk of PD was observed (RR, 0.85; 95% CI, 0.72-1.00; P = .05), and when the DDD of pioglitazone was greater than 438, the risk of PD in patients with diabetes was significantly decreased (P < .05) and showed an approximate linear correlation trend.
The sole use of retrospective cohort studies was noted to be a potential limitation of the study findings.
“The studies included in this study did not report the reaction of PD drug treatment, whether the PD exists in the family history, gene mutation, and other information, and it was uncertain whether these features have been included in the correction factors, which should be further explored,” they added.
The researchers concluded that more high-quality studies may be warranted to confirm the treatment effect of pioglitazone on PD prevention.
Reference
Chen L, Tao Y, Li J, Kang M. Pioglitazone use is associated with reduced risk of Parkinson’s disease in patients with diabetes: a systematic review and meta-analysis. J Clin Neurosci. 2022;106:154-158. doi:10.1016/j.jocn.2022.10.023
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More